Kymera Therapeutics, Inc.
KYMR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815442
In the last 90 days, Kymera Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 300 institutions reported holding it in 13F filings for Q3 2026, worth $11.1B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 18, 2026
- $10.3B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $4.16M in total
- 2
- 13F holdersQ3 2026, +26 vs. previous quarter
- 300
- 13F valueReported value at the end of Q3 2026
- $11.1B
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $39.2M
- −16.7% year over year
- Net income, FY2025
- -$311.4M
- No comparable prior period
- Free cash flow, FY2025
- -$234.3M
- No comparable prior period
- Revenue, Q3 FY2026
- $0
- −100.0% year over year
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 8.40M
- Shares sold short
- Change
- −770.6K
- −8.4% vs. previous
- Days to cover
- 10.49
- At average daily volume
Superinvestors holding KYMR, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding KYMR at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Kymera Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 (view filing)5:20 PM ET | Oct 1 | Same day | Mainolfi NelloChief Executive Officer | SSale | −30.0K | $113.80 | −$3.41M | −4.3%666.6K after | 6 lots10b5-1 |
| Sep 4, 2026 (view filing)6:00 PM ET | Sep 4 | Same day | Adams BrianChief Legal Officer | SSale | −6.37K | $116.83 | −$744.3K | −11.3%50.3K after | 3 lots |
| Jul 7, 2026 (view filing)8:00 PM ET | Jul 7 | Same day | Mainolfi NelloChief Executive Officer | SSale | −50.0K | $119.00 | −$5.95M | −7.0%666.6K after | 10b5-1 |
| Jul 2, 2026 (view filing)6:30 PM ET | Jun 30 | 2 days | Jacobs Bruce N.Chief Financial Officer | SSale | −77.1K | $114.96 | −$8.86M | −23.9%244.9K after | 8 lots10b5-1 |
| Jul 2, 2026 (view filing)6:30 PM ET | Jul 1 | 1 day | Goodman NoahChief Business Officer | SSale | −3.39K | $114.29 | −$387.3K | −6.7%47.2K after | 10b5-1 |
| Jul 2, 2026 (view filing)6:30 PM ET | Jul 1 | 1 day | Mainolfi NelloChief Executive Officer | SSale | −80.0K | $115.29 | −$9.22M | −10.7%666.6K after | 5 lots10b5-1 |
| Jul 2, 2026 (view filing)5:39 PM ET | Jun 29 | 3 days | Booth BruceDirector | SSale | −76.7K | $108.05 | −$8.28M | −14.2%462.9K after | Amended14 lots10b5-1 |
| Jun 30, 2026 (view filing) | Jun 29 | 1 day | Booth BruceDirector | SSale | −31.3K | $109.48 | −$3.42M | −6.3%461.8K after | 8 lots10b5-1 |
| Jun 30, 2026 (view filing) | Jun 26-29 | 4 days | Booth BruceDirector | SSale | −513.2K | $110.01 | −$56.5M | −52.4%466.1K after | 30 lots10b5-1 |
| Jun 26, 2026 (view filing)6:48 PM ET | Jun 26 | Same day | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | SSaleCommon Stock, $0.0001 par value | −1.58M | $106.50 | −$168.1M | −86.8%240.1K after | 3 lots |
Top 10 13F holders, Q3 2026
See all 300 holdersThe largest institutional positions in Kymera Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 12,568,921 | $1.41B | 0.06% | +219,665+1.8% | Added |
| Price T Rowe Associates Inc | 8,725,908 | $975.5M | 0.10% | +1,612,928+22.7% | Added |
| Baker Bros. Advisors LP | 8,657,242 | $967.8M | 4.60% | 00.0% | Unchanged |
| Avoro Capital Advisors LLC | 7,474,747 | $835.6M | 8.62% | 00.0% | Unchanged |
| BlackRock, Inc. | 5,825,416 | $651.2M | 0.01% | +287,206+5.2% | Added |
| T. Rowe Price Investment Management, Inc. | 5,736,316 | $641.3M | 0.45% | −520,945−8.3% | Reduced |
| BVF Inc | 3,872,052 | $432.9M | 14.24% | 00.0% | Unchanged |
| Wellington Management Group LLP | 3,706,994 | $414.4M | 0.07% | +31,966+0.9% | Added |
| Vanguard Capital Management LLC | 3,044,214 | $340.3M | 0.01% | +111,836+3.8% | Added |
| Vanguard Portfolio Management LLC | 2,978,521 | $333.0M | 0.02% | −13,672−0.5% | Reduced |
Holders of 5% or more of KYMR
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Kymera Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 14.30%11.7M shares | +3.10 ppfrom 11.20% | Feb 8, 20217 filings | May 6, 2026 | SEC |
| Baker Bros. Advisors LP | 13D/A | 10.90%8.68M shares | +1.40 ppfrom 9.50% | Feb 14, 20236 filings | Dec 11, 2025 | SEC |
| Price T Rowe Associates Inc | 13G/A | 10.70%8.87M shares | +2.10 ppfrom 8.60% | Feb 14, 20229 filings | Sep 8, 2026 | SEC |
| T. Rowe Price Investment Management, Inc. | 13G | 6.70%5.46M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.60%5.45M shares | +1.20 ppfrom 5.40% | Jul 17, 20252 filings | Oct 27, 2026 | SEC |